author-photo

Aditya Bardia

Harvard University
Mayo Clinic
Johns Hopkins University

451

Papers

12878

Citations

Citation Trend

Filter By

Papers (451) Sort By

Journal Conference Others

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Relationship of established risk factors with breast cancer subtypes.

2021 Cancer Medicine
Show All
- Source
- Cite
- Save
Citations (0)
Antibody drug conjugates for patients with breast cancer

2021 Current Problems in Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Landscape of GATA3 mutations identified from circulating tumor DNA clinical testing and their impact on disease outcomes in estrogen receptor-positive (ER+) metastatic breast cancers treated with endocrine therapies.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2– LA/mBC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Sacituzumab Govitecan For Metastatic Triple Negative Breast Cancer: Clinical Overview And Management Of Potential Toxicities.

2021 Oncologist
Show All
- Source
- Cite
- Save
Citations (1)
LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
91O Pooled analysis of patient (pt)-reported outcomes (PROs) in the MONALEESA (ML)-2, -3, and -7 trials: Additional results and key subgroup findings

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract SP012: Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine signaling inhibitors

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)